Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_assertion type Assertion NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_head.
- NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_assertion description "[We show that pharmacological inhibition of CD38 results in higher intracellular NAD(+) levels and that treatment of cell cultures with apigenin decreases global acetylation as well as the acetylation of p53 and RelA-p65.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_provenance.
- NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_assertion evidence source_evidence_literature NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_provenance.
- NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_assertion SIO_000772 23172919 NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_provenance.
- NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_assertion wasDerivedFrom befree-20140225 NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_provenance.
- NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_assertion wasGeneratedBy ECO_0000203 NP881819.RAzqT7ZYZfyI3hW8RYn1Hc9eBxJv2uMrbTr3Uk64RdVi8130_provenance.